Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 Oct 15;110(8):3064-70.
doi: 10.1182/blood-2007-04-067215. Epub 2007 Jun 14.

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease

Claudio G Brunstein  1 , Juliet N Barker, Daniel J Weisdorf, Todd E DeFor, Jeffrey S Miller, Bruce R Blazar, Philip B McGlave, John E Wagner
Affiliations
Clinical Trial

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease

Claudio G Brunstein et al. Blood. .

Abstract

We evaluated the efficacy of umbilical cord blood (UCB) in the setting of a nonmyeloablative regimen consisting of fludarabine (200 mg/m2), cyclophosphamide (50 mg/kg), and a single fraction of total body irradiation (200 cGy) with cyclosporine and mycophenolate mofetil for posttransplantation immunoprophylaxis. The target cell dose for the UCB graft was 3.0 x 10(7) nucleated cells/kg, resulting in the selection of a second partially human leukocyte antigen-matched UCB unit in 85%. One hundred ten patients with hematologic disease were enrolled. Neutrophil recovery was achieved in 92% at a median of 12 days. Incidences of grades III and IV acute and chronic graft-versus-host disease (GVHD) were 22% and 23%, respectively. Transplantation-related mortality was 26% at 3 years. Survival and event-free survival (EFS) at 3 years were 45% and 38%, respectively. Favorable risk factors for survival were absence of high-risk clinical features (Karnofsky 50-60, serious organ dysfunction, recent fungal infection, P < .01) and absence of severe GVHD (P = .04), and favorable risk factors for EFS were absence of high-risk clinical features (P < .01) and use of 2 UCB units (P = .07). These findings support the use of UCB after a nonmyeloablative conditioning as a strategy for extending the availability of transplantation therapy, particularly for older patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence of neutrophil recovery by day 42 and unsupported platelet recovery greater than 50 × 109/L at 6 months after nonmyeloablative umbilical cord blood transplantation. (A) Neutrophil recovery. (B) Unsupported platelet recovery.
Figure 2
Figure 2
Bone marrow chimerism 21, 100, 180, and 365 days after nonmyeloablative umbilical cord blood transplantation. The solid horizontal line indicates the median chimerism; ◇, patients with sustained donor engraftment; and ▴, patients who developed graft failure.
Figure 3
Figure 3
Cumulative incidence of grades II-IV (––) and grades III and IV (----) acute GVHD and 3-year treatment-related mortality after nonmyeloablative umbilical cord blood transplantation. (A) Incidences of GVHD. (B) Incidence of 3-year treatment-related mortality.
Figure 4
Figure 4
Cumulative proportion of 3-year event-free survival and overall survival for patients receiving either 1 (—) or 2 (---) UCB unit transplantation after a nonmyeloablative conditioning regimen. (A) Event-free survival. (B) Overall survival.
See this image and copyright information in PMC

References

    1. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–2275. - PubMed
    1. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–2285. - PubMed
    1. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104:3813–3820. - PubMed
    1. di Grazia C, Raiola AM, Van Lint MT, et al. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft. Haematologica. 2001;86:646–651. - PubMed
    1. Uzunel M, Remberger M, Sairafi D, et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation. 2006;82:913–919. - PubMed

Publication types

MeSH terms